Lecanemab: A new drug with potential to slow Alzheimer’s
Corenna Twiss reports on the development of lecanemab, a new monoclonal antibody drug which may be able to treat Alzheimer’s.
medicine
Continue reading
Oxford researchers contribute to global efforts in pandemic prediction
Andrea Lafleur reports on advancements in the prediction of global pandemics, where Oxford researchers such as Dr Amanda Rojek are key.
Vann: a virtual community against cancer
reports on a new app called Vann which aims to create a community among cancer patients as well as providing treatment tips.
From willow bark to aspirin: The evolution of modern medicine, through the rise and fall of ancient and medieval empires
Isra El Haddad reflects on the importance of ancient discoveries to the evolution of modern medicine and treatments.
University of Oxford will now use UCAT as admission test for medicine applications
Alina Ahsan evaluates the decision of the University of Oxford to switch to the UCAT admissions test for medicine.
How scientists are building a library of the brain’s dysfunctional pathways
SungJung Cho reports on a new study that has detailed dysfunctional neural circuits associated with neuropsychiatric disorders.
Hope for HIV vaccine—antibodies protect animals against infection in pilot study
Sinibaldo Romero Arocha reports on new findings that broadly neutralising antibodies confer protection against HIV in a primate study.
Lost legacies: Western medicine’s appropriation of Indigenous psychedelic wisdom
Athina Metaxa explores how the Western psychedelic renaissance can threaten Indigenous communities and initiatives created to mitigate such.
CBD: Miracle or myth?
Billie Delpino explores the growing use of CBD for mitigating various symptoms, and the extent to which CBD is supported by science.
New wave medicine: The clinical potential of non-hallucinogenic “designer psychedelics”
Sofia Luchanskaya discusses the clinical potential of psychedelics in treating mood and addiction disorders.